Vor Biopharma Inc. (VOR) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | 627.78M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $627.78M | (m) |
| 2026-03-31 | (m) | $-883.08M | (m) |
| 2025-12-31 | (m) | $-695.98M | (m) |
| 2025-09-30 | (m) | $-2.45B | (m) |
| 2025-06-30 | (m) | $-1.66B | (m) |
| 2025-03-31 | (m) | $-118.60M | (m) |
| 2024-12-31 | (m) | $-116.91M | (m) |
| 2024-09-30 | (m) | $-112.46M | (m) |
| 2024-06-30 | (m) | $-118.09M | (m) |
| 2024-03-31 | (m) | $-120.23M | (m) |
| 2023-12-31 | (m) | $-117.86M | (m) |
| 2023-09-30 | (m) | $-115.51M | (m) |
| 2023-06-30 | (m) | $-106.11M | (m) |
| 2023-03-31 | (m) | $-97.79M | (m) |
| 2022-12-31 | (m) | $-92.09M | (m) |
| 2022-09-30 | (m) | $-86.44M | (m) |
| 2022-06-30 | (m) | $-81.20M | (m) |
| 2022-03-31 | (m) | $-77.91M | (m) |
| 2021-12-31 | (m) | $-68.90M | (m) |
| 2021-09-30 | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) |
| 2020-12-31 | (m) | $-43.34M | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |